Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost
South Africa
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari,
Created on
April 29, 2024
Last modified
April 29, 2024
Page views
24584
Download
2
Documentation in PDF
Metadata
DDI/XML
JSON
- Data files
- SHERPA_Safetydata
addtional_comments (addtional_comments)
Data file: SHERPA_Safetydata
Overview
Valid:
5
Type:
Discrete
Width:
255
Range:
-
Format:
character
Questions and instructions
Categories
| Value | Category | Cases | |
|---|---|---|---|
| Only site redness observed in the injection site. | 1 |
20%
|
|
| Participant contacted telephonically and confirmed all local reactions resolved by 23/07/2022 | 1 |
20%
|
|
| Participant reported of feeling dizziness. Post vaccination. No medication taken and clinically stable | 1 |
20%
|
|
| Ppt given analgesia: Panado 500mg TDS PO (5/7) | 1 |
20%
|
|
| none | 1 |
20%
|
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.